Providers

The drug lowered inflammation, oxidative stress, and endothelial injury markers in women with INOCA and coronary microvascular dysfunction.

This article presents a case study of how stakeholders in one state came together to integrate practice and research that is a step beyond a learning health care system.

Patients’ misperceptions of statins and physicians’ limited knowledge of a hypercholesterolemia safety-net program warrant additional interventions to reduce barriers and improve care.

Byoung Chul Cho, MD, PhD, of the Yonsei University College of Medicine, discussed outcomes in the COCOON trial of an enhanced dermatologic regimen with amivantamab-lazertinib treatment.

Despite overall growth in the radiology workforce, the proportion of pediatric radiologists specifically decreased from 2016 to 2023.

This article reviews the safety, efficacy, and regulatory concerns related to compounded semaglutide, with a focus on how health care providers can offer guidance and education to patients.

Efren Flores, MD, of Harvard Medical School and Massachusetts General Hospital, discussed the findings of a subanalysis of the Screen ASSIST tobacco cessation clinical trial.

Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).

The treatment also showed signs of metabolic gains, with more benefit seen with the 50-mg dose than the 28-mg.

The findings add confidence to the role of ritlecitinib as a treatment option for severe alopecia areata while pointing the way toward more personalized approaches.

Emma Guttman-Yassky, MD, PhD, discusses promising hair regrowth results for alopecia areata treatments, emphasizing safety and rapid efficacy.

Despite reduced immune responses, immunization lowers infection rates and remains central to supportive care in patients with multiple myeloma.

A new joint guideline from the American Heart Association and the American College of Cardiology emphasizes early treatment, close perinatal blood pressure monitoring, and incorporating the PREVENT risk calculator to personalize care.

Psoriasis received the second-most funding of any pediatric dermatology condition, even though it ranked fifth in terms of disease burden.

Patients with small cell lung cancer (SCLC) experienced better responses to immune checkpoint inhibitors if they had higher levels of NOTCH1 expression in a recent study.

The findings may inform future studies on the therapeutic strategy for patients with small cell lung cancer (SCLC).

While observational studies have previously pointed to an association, being able to identify causation has been difficult due to overlapping risk factors and confounding variables.

A primary care–based collaborative care model significantly cut opioid use, though mental health outcomes remained unchanged.

Givinostat shows promise in delaying Duchenne muscular dystrophy (DMD) progression, enhancing mobility, and maintaining safety in long-term treatment.

Patients with severe sickle cell disease experienced significant quality of life improvements after receiving exagamglogene autotemcel gene therapy.

Families reported quality of life improvements when they used peanut oral immunotherapy instead of simply avoiding peanuts.

A new patient-centered methadone restart protocol enhances opioid use disorder treatment, improving safety and retention while personalizing care.

Targeted “Food is Medicine” interventions can help individuals with diet-sensitive chronic conditions improve their health, but nationally representative survey and qualitative interviews showed low awareness despite high interest among respondents.

Lebrikizumab shows sustained efficacy and safety in managing moderate to severe atopic dermatitis over 3 years, reducing the need for rescue therapies.

Matias Sanchez, MD, a hematologist-oncologist at University of Illinois Health, discussed strategies to deliver cutting-edge multiple myeloma care while mitigating costs.

By week 16, researchers found 87.8% of patients achieved a satisfactory humoral response.

Metabolic syndrome severity is a meaningful marker of chronic kidney disease risk even when patients do not have other major risk factors.

Despite the findings, existing data around cardiovascular risk in chronic lymphocytic leukemia (CLL) are limited, and more comprehensive information is needed to draw strong conclusions.

The findings are part of a new wave of research that uses artificial intelligence (AI) to hasten scientific discovery.

The study found no difference in physician communication scores between patients with advanced cancer and other illnesses, suggesting that discordance may stem from other dynamics.